Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘tarveda’

Tarveda Therapeutics to Present at the 2020 Biotech Showcase

Posted by fidest press agency su venerdì, 10 gennaio 2020

San Francisco, CA.January 13-15, 2020 at the Hilton Union Square the presentation will take place at 9:45am Pacific Time. Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2020 Biotech Showcase.
Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda currently has two Pentarin miniature drug conjugates in clinical trials. Its first clinical program, PEN-866, is its initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment across a wide range of solid tumor cancers, but which remains relatively dormant in normal tissue. PEN-866 is currently completing its Phase 1 dose escalation portion of its “all comers” trial of various types of solid tumors and is anticipating conclusion of this Phase 1 dose escalation study in the first quarter of 2020. Tarveda’s second clinical program, PEN-221, is a Pentarin miniature drug conjugate currently in clinical evaluation for the treatment of patients with solid tumors expressing somatostatin receptor 2, or SSTR2, on the cell surface such as neuroendocrine tumors and small cell lung cancer. PEN-221 is a proprietary asset discovered in-house and is currently progressing through its Phase 2a trial.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Tarveda Therapeutics to Present at the 2019 BIO CEO & Investor Conference

Posted by fidest press agency su mercoledì, 6 febbraio 2019

New York February 11-12, 2019 Marriot Marquis. The presentation will take place at 2:15pm Eastern Time on Monday, February 11 in the Gramercy room.
Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference.
In the presentation, Mr. Fromkin will provide an overview of the Company’s two clinical programs including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive neuroendocrine tumors and PEN-866, the first miniature drug conjugate from Tarveda’s HSP90 binding conjugate platform, which is being developed for the treatment of patients with solid tumors including but not limited to small cell lung cancer, pancreatic cancer and sarcomas.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »